UDK: 616.155.392.8
A.S. Lyamkina1, T.I. Pospelova1, L.M. Maslova2, L.A. Shpagina2, T.N. Kurbeteva3, E.V. Daragan3, O.V. Naumenko 3, A.V. Yudanov3
1ФГБОУ ВО «Новосибирский государственный медицинский университет» Министерства здравоохранения Российской Федерации; 2ГБУЗ НО «Городская клиническая больница № 2»; 3ГБУЗ НО «Государственная Новосибирская областная клиническая больница»
We have analyzed the therapy outcomes of chronic myeloid leukemia of patients, received imatinib treatment for more than 12 month (136 patients). Complete hematologic response (CHR) is attained in 88,2 % cases (120 patients), complete cytogenetic response (CCR) (ph+ <0%) – in 72,1 % cases (98 patients), major molecular response (MMR) – in 47,1 % cases (64 patients). The primary resistance to imatinib is observed in 20,6 % cases (28 patients), secondary – in 7,4 % cases (10 patients – 7 patients have lost the CHR and CCR and 3 patients have lost the CCR and MMR). The thirteen patients of those, who have primary or secondary resistance to imatinib have been treated with second-generation tyrosine kinase nhibitors (nilotinib, dasatinib) and in 84,6 % cases (11 patients) the CCR have been obtained, 5 patients (38,5 %) have attained the CCR and 4 patients (30,8 %) have achieved the MMR. Among all those patients, who have been treated with I and II generations tyrosine kinase inhibitors, 75,7 % patients have attained CCR, 50 % – MMR. We have estimated overall survival (OS) analysis and obtained following results: the median of OS have not been achieved, 5-years OS rate is estimated as 90 %, 10-years OS rate – more than 77 %, calculated 15-years OS – more than 60 %.
chronic myeloid leukemia, complete cytogenetic response, major molecular response, survival.
Лямкина Анна Сергеевна – к.м.н., доцент кафедры терапии, гематологии и трансфузиологии ФГБОУ ВО Новосибирский государственный медицинский университет Минздрава России, e-mail: anna_lyam@mail.ru